top of page
F2i: Pioneering a new approach to cancer therapy with an FRS2 inhibitor
Building upon my previous work on disrupting oncogenic signaling, I have continued my research into the fibroblast growth factor receptor
Oct 24, 2024
bottom of page
top of page
bottom of page